Intensity Therapeutics, Inc. SEC filings INTS
Intensity Therapeutics, Inc. has 246 filings in SEC EDGAR's recent list, going back to Jan 18, 2013. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 4 | Insider transaction | Jul 20, 2026 | Jul 16, 2026 |
| 4 | Insider transaction | Jul 20, 2026 | Jul 16, 2026 |
| 4 | Insider transaction | Jul 20, 2026 | Jul 16, 2026 |
| 4 | Insider transaction | Jul 20, 2026 | Jul 16, 2026 |
| 4 | Insider transaction | Jul 20, 2026 | Jul 16, 2026 |
| 4 | Insider transaction | Jul 20, 2026 | Jul 16, 2026 |
| 4 | Insider transaction | Jul 20, 2026 | Jul 16, 2026 |
| 4 | Insider transaction | Jul 1, 2026 | Jun 30, 2026 |
| 4 | Insider transaction | Jul 1, 2026 | Jun 30, 2026 |
| 4 | Insider transaction | Mar 30, 2026 | Mar 26, 2026 |
| 4 | Insider transaction | Jan 5, 2026 | Dec 31, 2025 |
| 4 | Insider transaction | Jan 5, 2026 | Dec 31, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Jul 9, 2025 | — |
| 4 | Insider transaction | Jul 2, 2025 | Jun 30, 2025 |
| 4 | Insider transaction | Jul 2, 2025 | Jun 30, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2025 | — |
| 4 | Insider transaction | May 6, 2025 | May 2, 2025 |
| 4 | Insider transaction | May 6, 2025 | May 2, 2025 |
| 4 | Insider transaction | May 6, 2025 | May 2, 2025 |
| 4 | Insider transaction | May 6, 2025 | May 2, 2025 |
| 4 | Insider transaction | May 6, 2025 | May 2, 2025 |
| 4 | Insider transaction | May 6, 2025 | May 2, 2025 |
| 4 | Insider transaction | May 6, 2025 | May 2, 2025 |
| 4 | Insider transaction | May 6, 2025 | May 2, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 14, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Dec 30, 2024 | — |
| 4 | Insider transaction | Oct 23, 2024 | Oct 21, 2024 |
| 4 | Insider transaction | Oct 23, 2024 | Oct 21, 2024 |
| SC 13G | Ownership over 5% (passive) | Jun 7, 2024 | — |
| 4 | Insider transaction | Jun 7, 2024 | Jun 5, 2024 |
| 4 | Insider transaction | May 15, 2024 | May 14, 2024 |
| 3 | Initial insider ownership | May 15, 2024 | May 14, 2024 |
| 4 | Insider transaction | Mar 7, 2024 | Mar 6, 2024 |
| 4 | Insider transaction | Mar 7, 2024 | Mar 6, 2024 |
| 4 | Insider transaction | Mar 7, 2024 | Mar 6, 2024 |
| 4 | Insider transaction | Mar 7, 2024 | Mar 6, 2024 |
| 4 | Insider transaction | Mar 7, 2024 | Mar 6, 2024 |
| SC 13G | Ownership over 5% (passive) | Feb 13, 2024 | — |
| 4 | Insider transaction | Dec 12, 2023 | Dec 11, 2023 |
| 3 | Initial insider ownership | Dec 12, 2023 | Dec 11, 2023 |
| 4 | Insider transaction | Jul 21, 2023 | Jul 19, 2023 |
| 3 | Initial insider ownership | Jun 29, 2023 | Jun 29, 2023 |
| 3 | Initial insider ownership | Jun 29, 2023 | Jun 29, 2023 |
| 3 | Initial insider ownership | Jun 29, 2023 | Jun 29, 2023 |
| 3 | Initial insider ownership | Jun 29, 2023 | Jun 29, 2023 |
| 3 | Initial insider ownership | Jun 29, 2023 | Jun 29, 2023 |
| 3 | Initial insider ownership | Jun 29, 2023 | Jun 29, 2023 |
Showing 48 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- INTS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Shelton, CT
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1567264
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.